CVS Health Aktie News

CVS Health Corporation is rated a Buy with an 18% upside to a $97 price target, citing robust business momentum and undervaluation. CVS posted a strong FQ2 2025 double-beat, with revenue up 8.4% and continued double-digit growth in health services and pharmacy segments. CVS stock trades at a significant valuation discount to sector and market averages, despite steady top-line growth and a 3.25%...

CVS Health is shuttering 16 Oak Street Health Centers, or 7% of the total number of the senior-focused primary care locations the company operates across the U.S.

Over the past ten years, CVS Health stock (NYSE: CVS) has returned $31 billion to shareholders in the form of cash through dividends and buybacks. This shareholder-focused strategy has delivered exceptional results in 2025, with the stock posting a remarkable 81% year-to-date return, representing one of the most dramatic healthcare sector turnarounds after suffering a 42% decline in 2024 and de...

Slow and steady performers do better over the long term.

Annual premiums for U.S. families with employer-sponsored health insurance in 2025 rose 6% to nearly $27,000, reflecting higher spending on popular weight-loss treatments and other prescription drugs, according to a survey by health-policy organization KFF.

CVS Pharmacy said it is now serving more than 9 million former Rite Aid and Bartell Drugs patients after completing its acquisition of select assets of the now-closed Rite Aid.

CVS allegedly misled investors on its Health Care Benefits segment; rising medical costs and poor forecasts led to repeated guidance cuts and stock drops.

WOONSOCKET, R.I. , Oct. 16, 2025 /PRNewswire/ -- CVS Health (NYSE: CVS) today announced it will support simpler access to more affordable fertility treatments for all Americans through its CVS Specialty Pharmacy and make it easier to pick up fertility medication at its 9,000 community pharmacy locations.